Biotechnologies in haematological malignancies.
The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.
Foà
R
R
Dipartimento di Scienze Biomediche e Oncologia Umana, Universit di Torino.
Reato
G
G
Guarini
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001709:Biotechnology; D005819:Genetic Markers; D019337:Hematologic Neoplasms / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D018664:Interleukin-12 / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D018365:Neoplasm, Residual / Q000175:diagnosis; D011379:Prognosis
D000970:Antineoplastic Agents; D005819:Genetic Markers; D016898:Interferon-alpha; D007376:Interleukin-2; D018664:Interleukin-12